Comparative aspects of the care of familial hypercholesterolemia in the "Ten Countries Study"

Pang J 1 , Chan DC 1 , Hu M 2 , Muir LA 3 , Kwok S 4 , Charng MJ 5 Show all authors , Florkowski CM 3 , George PM 3 , Lin J 6 , Loi DD 7 , Marais AD 8 , Nawawi HM 9 , Gonzalez-Santos LE 10 , Su TC 11 , Truong TH 7 , Santos RD 12 , Soran H 4 , Tomlinson B 2 , Yamashita S 13 , Ademi Z 14 , Watts GF 15

Affiliations 

  • 1 School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, Perth, Western Australia, Australia
  • 2 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR
  • 3 Biochemistry and Pathology, Canterbury Health Laboratories, Lipid Clinic, Christchurch Hospital, University of Otago, Christchurch, New Zealand
  • 4 University of Manchester, Faculty of Biology, Medicine and Health, Manchester, United Kingdom; Cardiovascular Trials Unit, Clinical Trial Management Office, Manchester Royal Infirmary, Manchester, United Kingdom
  • 5 Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan
  • 6 Department of Atherosclerosis, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China
  • 7 Department of Cardiology, Hanoi Medical University, Hanoi, Vietnam; Vietnam National Heart Institute, Bach Mai Hospital, Hanoi, Vietnam
  • 8 Division of Chemical Pathology, University of Cape Town Health Science Faculty, South Africa
  • 9 Institute of Pathology, Laboratory and Forensic Medicine (I-PPerForM), Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Selangor, Malaysia
  • 10 Department of Cardiology, Section of Preventive Cardiology, UP-Philippine General Hospital, Manila, Philippines
  • 11 Departments of Environmental and Occupational Medicine, Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
  • 12 Lipid Clinic Heart Institute (InCor), University of São Paulo Medical School Hospital and Hospital Israelita Albert Einstein, São Paulo, Brazil
  • 13 Departments of Cardiovascular Medicine and Community Medicine, Osaka University Graduate School of Medicine, Osaka, Japan; Rinku General Medical Center, Osaka, Japan
  • 14 School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
  • 15 School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, Perth, Western Australia, Australia; Department of Cardiology, Lipid Disorders Clinic, Cardiometabolic Services, Royal Perth Hospital, Perth, Western Australia, Australia. Electronic address: gerald.watts@uwa.edu.au
J Clin Lipidol, 2019 01 25;13(2):287-300.
PMID: 30797720 DOI: 10.1016/j.jacl.2019.01.009

Abstract

BACKGROUND: There is a lack of information on the health care of familial hypercholesterolemia (FH).

OBJECTIVE: The objective of this study was to compare the health care of FH in countries of the Asia-Pacific region and Southern Hemisphere.

METHODS: A series of questionnaires were completed by key opinion leaders from selected specialist centers in 12 countries concerning aspects of the care of FH, including screening, diagnosis, risk assessment, treatment, teaching/training, and research; the United Kingdom (UK) was used as the international benchmark.

RESULTS: The estimated percentage of patients diagnosed with the condition was low (overall <3%) in all countries, compared with ∼15% in the UK. Underdetection of FH was associated with government expenditure on health care (ϰ = 0.667, P 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications